Author

D. Salzig

Mittelhessen University of Applied Sciences, Germany

2 articles in our journals

Articles where this person is an author, newest first. People are matched by their name as printed (no ORCID iD is recorded for them), not by name alone; search the name as text to find namesakes too.

Research ArticleOpen accessInfluence of Process Conditions on Measles Virus StabilityK. Weiss, D. Salzig, J. Gerstenberger et al.Recombinant measles viruses are currently tested in clinical trials as oncolytic agent to be applied in cancer therapy. Contrary to their use as vaccine where 103 infectious virus particles per dose are needed, for cancer therapy 109 virus particles should be provided per dose. This leads to other challenges for the production process when compared to vaccine production. This study … …American Journal of Biochemistry and Biotechnology, Vol. 9, Issue 3 · 21 Sep 2013 · 9,949 accessesView PDF Cite

Research ArticleOpen accessKEY PARAMETERS OF MEASLES VIRUS PRODUCTION FOR ONCOLYTIC VIROTHERAPYK. Weiss, D. Salzig, M. D. Mühlebach et al.Attenuated measles virus has revealed selective tumor cell killing and is currently tested in clinical trials for the therapy of cancer patients. The amount of infectious particles per dose needed for oncolytic therapy can be more than a million times higher compared to vaccination. This requires highly effective production processes which guarantee the measles virus quantities needed for its use … …American Journal of Biochemistry and Biotechnology, Vol. 8, Issue 2 · 22 Jun 2012 · 9,785 accessesView PDF Cite